UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.80
+0.63%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.32
- Revenue estimate
- $902.8K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.47
- Revenue actual
- —
- Revenue estimate
- $22.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +5.1%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $25
- PT range
- $15 – $50
- Analysts
- 5
5 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.47 | -$0.06 | Beat 87.26% | — |
| May 12, 2026 | -$0.46 | -$0.54 | Miss -17.68% | — |
| Mar 30, 2026 | -$0.47 | -$0.86 | Miss -83.13% | — |
| Nov 12, 2025 | -$0.59 | -$0.39 | Beat 33.90% | — |
| Aug 14, 2025 | -$0.70 | -$0.52 | Beat 25.71% | — |
| Mar 31, 2025 | -$0.13 | -$0.26 | Miss -100.00% | — |
| Aug 14, 2024 | -$0.23 | -$0.15 | Beat 34.78% | — |
| Nov 14, 2023 | -$0.13 | -$0.13 | In line | — |
| Aug 14, 2023 | -$0.39 | -$0.29 | Beat 25.64% | — |
| May 16, 2023 | -$0.36 | -$0.29 | Beat 19.44% | $675.0K |
| Mar 31, 2023 | $0.24 | -$0.35 | Miss -245.83% | — |
| Nov 14, 2022 | -$0.35 | -$0.37 | Miss -5.71% | $951.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026